H. R. 6—44 
SEC. 3014. STRENGTHENING FDA AND CBP COORDINATION AND 
CAPACITY. 
(a) IN GENERAL.—The Secretary of Health and Human Services 
(referred to in this section as the ‘‘Secretary’’), acting through the 
Commissioner of Food and Drugs, shall coordinate with the Sec-
retary of Homeland Security to carry out activities related to cus-
toms and border protection and in response to illegal controlled 
substances and drug imports, including at sites of import (such 
as international mail facilities), that will provide improvements 
to such facilities, technologies, and inspection capacity. Such Secre-
taries may carry out such activities through a memorandum of 
understanding between the Food and Drug Administration and 
the U.S. Customs and Border Protection. 
(b) FDA IMPORT FACILITIES AND INSPECTION CAPACITY.— 
(1) IN GENERAL.—In carrying out this section, the Secretary 
shall, in collaboration with the Secretary of Homeland Security 
and the Postmaster General of the United States Postal Service, 
provide that import facilities in which the Food and Drug 
Administration operates or carries out activities related to drug 
imports within the international mail facilities include— 
(A) facility upgrades and improved capacity in order 
to increase and improve inspection and detection capabili-
ties, which may include, as the Secretary determines appro-
priate— 
(i) improvements to facilities, such as upgrades 
or renovations, and support for the maintenance of 
existing import facilities and sites to improve coordina-
tion between Federal agencies; 
(ii) improvements in equipment and information 
technology 
enhancement 
to 
identify 
unapproved, 
counterfeit, or other unlawful controlled substances for 
destruction; 
(iii) the construction of, or upgrades to, laboratory 
capacity for purposes of detection and testing of 
imported goods; 
(iv) upgrades to the security of import facilities; 
and 
(v) innovative technology and equipment to facili-
tate improved and near-real-time information sharing 
between the Food and Drug Administration, the 
Department of Homeland Security, and the United 
States Postal Service; and 
(B) innovative technology, including controlled sub-
stance 
detection 
and 
testing 
equipment 
and 
other 
applicable technology, in order to collaborate with the U.S. 
Customs and Border Protection to share near-real-time 
information, including information about test results, as 
appropriate. 
(2) INNOVATIVE
TECHNOLOGY.—Any technology used in 
accordance with paragraph (1)(B) shall be interoperable with 
technology used by other relevant Federal agencies, including 
the U.S. Customs and Border Protection, as the Secretary deter-
mines appropriate and practicable. 
(c) REPORT.—Not later than 6 months after the date of enact-
ment of this Act, the Secretary, in consultation with the Secretary 
of Homeland Security and the Postmaster General of the United 
States Postal Service, shall report to the Committee on Energy
H. R. 6—45 
and Commerce and the Committee on Homeland Security of the 
House of Representatives and the Committee on Health, Education, 
Labor, and Pensions and the Committee on Homeland Security 
and Governmental Affairs of the Senate on the implementation 
of this section, including a summary of progress made toward 
near-real-time information sharing and the interoperability of such 
technologies. 
CHAPTER 3—STOP ILLICIT DRUG IMPORTATION 
SEC. 3021. SHORT TITLE. 
This chapter may be cited as the ‘‘Stop Illicit Drug Importation 
Act of 2018’’. 
SEC. 3022. RESTRICTING ENTRANCE OF ILLICIT DRUGS. 
(a) FOOD AND DRUG ADMINISTRATION AND U.S. CUSTOMS AND 
BORDER PROTECTION COOPERATION.— 
(1) IN
GENERAL.—The Secretary of Health and Human 
Services (referred to in this section as the ‘‘Secretary’’), acting 
through the Commissioner of Food and Drugs and in consulta-
tion with the U.S. Customs and Border Protection, shall develop 
and periodically update a mutually agreed upon list of the 
controlled substances that the Secretary will refer to U.S. Cus-
toms and Border Protection, unless the Secretary and U.S. 
Customs and Border Protection agree otherwise, when such 
substances are offered for import via international mail and 
appear to violate the Controlled Substances Act (21 U.S.C. 
801 et seq.), the Controlled Substances Import and Export 
Act (21 U.S.C. 951 et seq.), the Federal Food, Drug, and Cos-
metic Act (21 U.S.C. 301 et seq.), or any other applicable 
law. The Secretary shall transfer controlled substances on such 
list to the U.S. Customs and Border Protection. If the Secretary 
identifies additional packages that appear to be the same as 
such package containing a controlled substance, such additional 
packages may also be transferred to U.S. Customs and Border 
Protection. The U.S. Customs and Border Protection shall 
receive such packages consistent with the requirements of the 
Controlled Substances Act (21 U.S.C. 801 et seq.). 
(2) REPORT.—Not later than 9 months after the date of 
enactment of this Act, the Secretary, acting through the 
Commissioner of Food and Drugs and in consultation with 
the Secretary of Homeland Security, shall report to the Com-
mittee on Energy and Commerce of the House of Representa-
tives and the Committee on Health, Education, Labor, and 
Pensions of the Senate on the implementation of this section. 
(b) DEBARMENT, TEMPORARY DENIAL OF APPROVAL, AND SUSPEN-
SION.— 
(1) PROHIBITED ACT.—Section 301(cc) of the Federal Food, 
Drug, and Cosmetic Act (21 U.S.C. 331(cc)) is amended— 
(A) by inserting ‘‘or a drug’’ after ‘‘food’’; and 
(B) by inserting ‘‘from such activity’’ after ‘‘person 
debarred’’. 
(2) DEBARMENT.—Section 306(b) of the Federal Food, Drug, 
and Cosmetic Act (21 U.S.C. 335a(b)) is amended— 
(A) in paragraph (1)— 
(i) in the matter preceding subparagraph (A), by 
inserting ‘‘or (3)’’ after ‘‘paragraph (2)’’;
H. R. 6—46 
(ii) in subparagraph (A), by striking the comma 
at the end and inserting a semicolon; 
(iii) in subparagraph (B), by striking ‘‘, or’’ and 
inserting a semicolon; 
(iv) in subparagraph (C), by striking the period 
and inserting ‘‘; or’’; and 
(v) by adding at the end the following: 
‘‘(D) a person from importing or offering for import 
into the United States a drug.’’; 
(B) in paragraph (3)— 
(i) in the heading, by inserting ‘‘OR DRUG’’ after 
‘‘FOOD’’; 
(ii) in subparagraph (A), by striking ‘‘; or’’ and 
inserting a semicolon; 
(iii) in subparagraph (B), by striking the period 
and inserting a semicolon; and 
(iv) by adding at the end the following: 
‘‘(C) the person has been convicted of a felony for 
conduct relating to the importation into the United States 
of any drug or controlled substance (as defined in section 
102 of the Controlled Substances Act); 
‘‘(D) the person has engaged in a pattern of importing 
or offering for import— 
‘‘(i) controlled substances that are prohibited from 
importation under section 401(m) of the Tariff Act 
of 1930 (19 U.S.C. 1401(m)); or 
‘‘(ii) adulterated or misbranded drugs that are— 
‘‘(I) not designated in an authorized electronic 
data interchange system as a product that is regu-
lated by the Secretary; or 
‘‘(II) knowingly or intentionally falsely des-
ignated in an authorized electronic data inter-
change system as a product that is regulated by 
the Secretary.’’; and 
(C) by adding at the end the following: 
‘‘(5) DEFINITION.—For purposes of paragraph (3)(D), the 
term ‘pattern of importing or offering for import’ means 
importing or offering for import a drug described in clause 
(i) or (ii) of paragraph (3)(D) in an amount, frequency, or 
dosage that is inconsistent with personal or household use 
by the importer.’’. 
(c) IMPORTS AND EXPORTS.—Section 801(a) of the Federal Food, 
Drug, and Cosmetic Act (21 U.S.C. 381(a)), as amended, is further 
amended— 
(1) by striking ‘‘, then such article shall be refused admis-
sion’’ inserting ‘‘or (5) such article is being imported or offered 
for import in violation of section 301(cc), then any such article 
described in any of clauses (1) through (5) shall be refused 
admission’’; 
(2) by inserting ‘‘If it appears from the examination of 
such samples or otherwise that the article is a counterfeit 
drug, such article shall be refused admission.’’ before ‘‘With 
respect to an article of food, if importation’’; and 
(3) by striking ‘‘Clause (2) of the third sentence’’ and all 
that follows through the period at the end and inserting the 
following: ‘‘Neither clause (2) nor clause (5) of the third sentence 
of this subsection shall be construed to prohibit the admission
H. R. 6—47 
of narcotic drugs, the importation of which is permitted under 
the Controlled Substances Import and Export Act.’’. 
(d) CERTAIN ILLICIT ARTICLES.—Section 801 of the Federal Food, 
Drug, and Cosmetic Act (21 U.S.C. 381), as amended, is amended 
by adding at the end the following— 
‘‘(u) ILLICIT ARTICLES CONTAINING ACTIVE PHARMACEUTICAL 
INGREDIENTS.— 
‘‘(1) IN GENERAL.—For purposes of this section, an article 
that is being imported or offered for import into the United 
States may be treated by the Secretary as a drug if the article— 
‘‘(A) is not— 
‘‘(i) accompanied by an electronic import entry for 
such article submitted using an authorized electronic 
data interchange system; and 
‘‘(ii) designated in such a system as an article 
regulated by the Secretary (which may include regula-
tion as a drug, a device, a dietary supplement, or 
other product that is regulated under this Act); and 
‘‘(B) is an ingredient that presents significant public 
health concern and is, or contains— 
‘‘(i) an active ingredient in a drug— 
‘‘(I) that is approved under section 505 or 
licensed under section 351 of the Public Health 
Service Act; or 
‘‘(II) for which— 
‘‘(aa) an investigational use exemption has 
been authorized under section 505(i) of this 
Act or section 351(a) of the Public Health 
Service Act; and 
‘‘(bb) a substantial clinical investigation 
has been instituted, and such investigation 
has been made public; or 
‘‘(ii) a substance that has a chemical structure 
that is substantially similar to the chemical structure 
of an active ingredient in a drug or biological product 
described in subclause (I) or (II) of clause (i). 
‘‘(2) EFFECT.—This subsection shall not be construed to 
bear upon any determination of whether an article is a drug 
within the meaning of section 201(g), other than for the pur-
poses described in paragraph (1).’’. 
CHAPTER 4—SECURING OPIOIDS AND UNUSED NAR-
COTICS WITH DELIBERATE DISPOSAL AND PACK-
AGING 
SEC. 3031. SHORT TITLE. 
This chapter may be cited as the ‘‘Securing Opioids and Unused 
Narcotics with Deliberate Disposal and Packaging Act of 2018’’ 
or the ‘‘SOUND Disposal and Packaging Act’’. 
SEC. 3032. SAFETY-ENHANCING PACKAGING AND DISPOSAL FEATURES. 
(a) DELIBERATE
DISPOSAL
AND
PACKAGING
ELEMENTS
OF 
STRATEGY.—Section 505–1(e) of the Federal Food, Drug, and Cos-
metic Act (21 U.S.C. 355–1(e)) is amended by adding at the end 
the following: 
‘‘(4) PACKAGING AND DISPOSAL.—The Secretary may require 
a risk evaluation mitigation strategy for a drug for which
H. R. 6—48 
there is a serious risk of an adverse drug experience described 
in subparagraph (B) or (C) of subsection (b)(1), taking into 
consideration the factors described in subparagraphs (C) and 
(D) of subsection (f)(2) and in consultation with other relevant 
Federal agencies with authorities over drug disposal packaging, 
which may include requiring that— 
‘‘(A) the drug be made available for dispensing to cer-
tain patients in unit dose packaging, packaging that pro-
vides a set duration, or another packaging system that 
the Secretary determines may mitigate such serious risk; 
or 
‘‘(B) the drug be dispensed to certain patients with 
a safe disposal packaging or safe disposal system for pur-
poses of rendering drugs nonretrievable (as defined in sec-
tion 1300.05 of title 21, Code of Federal Regulations (or 
any successor regulation)) if the Secretary determines that 
such safe disposal packaging or system may mitigate such 
serious risk and is sufficiently available.’’. 
(b) ASSURING ACCESS AND MINIMIZING BURDEN.—Section 505– 
1(f)(2)(C) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
355–1(f)(2)(C)) is amended— 
(1) in clause (i) by striking ‘‘and’’ at the end; and 
(2) by adding at the end the following: 
‘‘(iii) patients with functional limitations; and’’. 
(c) APPLICATION TO ABBREVIATED NEW DRUG APPLICATIONS.— 
Section 505–1(i) of the Federal Food, Drug, and Cosmetic Act (21 
U.S.C. 355–1(i)) is amended— 
(1) in paragraph (1)— 
(A) by redesignating subparagraph (B) as subpara-
graph (C); and 
(B) inserting after subparagraph (A) the following: 
‘‘(B) A packaging or disposal requirement, if required 
under subsection (e)(4) for the applicable listed drug.’’; and 
(2) in paragraph (2)— 
(A) in subparagraph (A), by striking ‘‘and’’ at the end; 
(B) by redesignating subparagraph (B) as subpara-
graph (C); and 
(C) by inserting after subparagraph (A) the following: 
‘‘(B) shall permit packaging systems and safe disposal 
packaging or safe disposal systems that are different from 
those required for the applicable listed drug under sub-
section (e)(4); and’’. 
(d) GAO REPORT.—Not later than 12 months after the date 
of enactment of this Act, the Comptroller General of the United 
States shall prepare and submit to Congress a report containing— 
(1) a description of available evidence, if any, on the 
effectiveness of site-of-use, in-home controlled substance dis-
posal products and packaging technologies; 
(2) an evaluation of existing reference standards with 
respect to controlled substance disposal products and packaging 
technologies, including any such standards established by a 
standards development organization, and how such standards 
should be considered in ensuring effectiveness of such products 
and technologies; 
(3) identification of ways in which such disposal products 
intended for use by patients, consumers, and other end users 
that are not registrants under the Controlled Substances Act
H. R. 6—50 
to reduced effectiveness, that the Secretary determines 
should be included in the labeling of the drug’’; 
(2) in clause (i) of subparagraph (B), by inserting before 
the semicolon ‘‘, or new effectiveness information’’; 
(3) in subparagraph (C) by striking ‘‘safety information’’ 
and inserting ‘‘safety or new effectiveness information’’; and 
(4) in subparagraph (E) by striking ‘‘safety information’’ 
and inserting ‘‘safety or new effectiveness information’’. 
(c) GUIDANCE.—Not less than one year after the date of enact-
ment of this Act, the Secretary of Health and Human Services 
shall issue guidance regarding the circumstances under which the 
Food and Drug Administration may require postmarket studies 
or clinical trials to assess the potential reduction in effectiveness 
of a drug and how such reduction in effectiveness could result 
in a change to the benefits of the drug and the risks to the patient. 
Such guidance shall also address how the Food and Drug Adminis-
tration may apply this section and the amendments made thereby 
with respect to circumstances under which the Food and Drug 
Administration may require postmarket studies or clinical trials 
and safety labeling changes related to the use of controlled sub-
stances for acute or chronic pain. 
Subtitle B—Controlled Substance 
Provisions 
CHAPTER 1—MORE FLEXIBILITY WITH RESPECT TO 
MEDICATION-ASSISTED TREATMENT FOR OPIOID USE 
DISORDERS 
SEC. 3201. ALLOWING FOR MORE FLEXIBILITY WITH RESPECT TO 
MEDICATION-ASSISTED TREATMENT FOR OPIOID USE DIS-
ORDERS. 
(a) CONFORMING APPLICABLE NUMBER.—Subclause (II) of sec-
tion 303(g)(2)(B)(iii) of the Controlled Substances Act (21 U.S.C. 
823(g)(2)(B)(iii)) is amended to read as follows: 
‘‘(II) The applicable number is— 
‘‘(aa) 100 if, not sooner than 1 year after the date 
on which the practitioner submitted the initial notification, 
the practitioner submits a second notification to the Sec-
retary of the need and intent of the practitioner to treat 
up to 100 patients; 
‘‘(bb) 
100 
if 
the 
practitioner 
holds 
additional 
credentialing, as defined in section 8.2 of title 42, Code 
of Federal Regulations (or successor regulations); 
‘‘(cc) 100 if the practitioner provides medication- 
assisted treatment (MAT) using covered medications (as 
such terms are defined in section 8.2 of title 42, Code 
of Federal Regulations (or successor regulations)) in a quali-
fied practice setting (as described in section 8.615 of title 
42, Code of Federal Regulations (or successor regulations)); 
or 
‘‘(dd) 275 if the practitioner meets the requirements 
specified in sections 8.610 through 8.655 of title 42, Code 
of Federal Regulations (or successor regulations).’’. 
(b) ELIMINATING ANY TIME LIMITATION
FOR NURSE PRACTI-
TIONERS
AND
PHYSICIAN
ASSISTANTS
TO
BECOME
QUALIFYING
H. R. 6—51 
PRACTITIONERS.—Clause (iii) of section 303(g)(2)(G) of the Con-
trolled Substances Act (21 U.S.C. 823(g)(2)(G)) is amended— 
(1) in subclause (I), by striking ‘‘or’’ at the end; and 
(2) by amending subclause (II) to read as follows: 
‘‘(II) a qualifying other practitioner, as defined in clause 
(iv), who is a nurse practitioner or physician assistant; 
or’’. 
(c) IMPOSING A TIME LIMITATION FOR CLINICAL NURSE SPECIAL-
ISTS, CERTIFIED REGISTERED NURSE ANESTHETISTS, AND CERTIFIED 
NURSE MIDWIFES TO BECOME QUALIFYING PRACTITIONERS.—Clause 
(iii) of section 303(g)(2)(G) of the Controlled Substances Act (21 
U.S.C. 823(g)(2)(G)), as amended by subsection (b), is further 
amended by adding at the end the following: 
‘‘(III) for the period beginning on October 1, 2018, 
and ending on October 1, 2023, a qualifying other practi-
tioner, as defined in clause (iv), who is a clinical nurse 
specialist, certified registered nurse anesthetist, or certified 
nurse midwife.’’. 
(d) DEFINITION OF QUALIFYING OTHER PRACTITIONER.—Section 
303(g)(2)(G)(iv) of the Controlled Substances Act (21 U.S.C. 
823(g)(2)(G)(iv)) is amended by striking ‘‘nurse practitioner or physi-
cian assistant’’ each place it appears and inserting ‘‘nurse practi-
tioner, clinical nurse specialist, certified registered nurse anes-
thetist, certified nurse midwife, or physician assistant’’. 
(e) REPORT BY SECRETARY.—Not later than 2 years after the 
date of the enactment of this Act, the Secretary of Health and 
Human Services, in consultation with the Drug Enforcement 
Administration, shall submit to Congress a report that assesses 
the care provided by qualifying practitioners (as defined in section 
303(g)(2)(G)(iii) of the Controlled Substances Act (21 U.S.C. 
823(g)(2)(G)(iii))) who are treating, in the case of physicians, more 
than 100 patients, and in the case of qualifying practitioners who 
are not physicians, more than 30 patients. Such report shall include 
recommendations on future applicable patient number levels and 
limits. In preparing such report, the Secretary shall study, with 
respect to opioid use disorder treatment— 
(1) the average frequency with which qualifying practi-
tioners see their patients; 
(2) the average frequency with which patients receive coun-
seling, including the rates by which such counseling is provided 
by such a qualifying practitioner directly, or by referral; 
(3) the frequency of toxicology testing, including the average 
frequency with which random toxicology testing is adminis-
tered; 
(4) the average monthly patient caseload for each type 
of qualifying practitioner; 
(5) the treatment retention rates for patients; 
(6) overdose and mortality rates; and 
(7) any available information regarding the diversion of 
drugs by patients receiving such treatment from such a quali-
fying practitioner. 
SEC. 3202. MEDICATION-ASSISTED TREATMENT FOR RECOVERY FROM 
SUBSTANCE USE DISORDER. 
(a) WAIVERS FOR MAINTENANCE TREATMENT OR DETOXIFICA-
TION.—Section 303(g)(2)(G)(ii) of the Controlled Substances Act (21
H. R. 6—52 
U.S.C. 823(g)(2)(G)(ii)) is amended by adding at the end the fol-
lowing: 
‘‘(VIII) The physician graduated in good standing from 
an accredited school of allopathic medicine or osteopathic medi-
cine in the United States during the 5-year period immediately 
preceding the date on which the physician submits to the 
Secretary a written notification under subparagraph (B) and 
successfully completed a comprehensive allopathic or osteo-
pathic medicine curriculum or accredited medical residency 
that— 
‘‘(aa) included not less than 8 hours of training on 
treating and managing opioid-dependent patients; and 
‘‘(bb) included, at a minimum— 
‘‘(AA) the training described in items (aa) through 
(gg) of subclause (IV); and 
‘‘(BB) training with respect to any other best prac-
tice the Secretary determines should be included in 
the curriculum, which may include training on pain 
management, including assessment and appropriate 
use of opioid and non-opioid alternatives.’’. 
(b) TREATMENT FOR CHILDREN.—The Secretary of Health and 
Human Services shall consider ways to ensure that an adequate 
number of qualified practitioners, as defined in subparagraph (G)(ii) 
of section 303(g)(2) of the Controlled Substances Act (21 U.S.C. 
823(g)(2)), who have a specialty in pediatrics or the treatment 
of children or adolescents, are granted a waiver under such section 
303(g)(2) to treat children and adolescents with substance use dis-
orders. 
(c) TECHNICAL AMENDMENT.—Section 102(24) of the Controlled 
Substances Act (21 U.S.C. 802(24)) is amended by striking ‘‘Health, 
Education, and Welfare’’ and inserting ‘‘Health and Human Serv-
ices’’. 
SEC. 3203. GRANTS TO ENHANCE ACCESS TO SUBSTANCE USE DIS-
ORDER TREATMENT. 
(a) IN GENERAL.—The Secretary of Health and Human Services 
shall establish a grant program under which the Secretary may 
make grants to accredited schools of allopathic medicine or osteo-
pathic medicine and teaching hospitals located in the United States 
to support the development of curricula that meet the requirements 
under subclause (VIII) of section 303(g)(2)(G)(ii) of the Controlled 
Substances Act, as added by section 3202(a) of this Act. 
(b) AUTHORIZATION OF APPROPRIATIONS.—There is authorized 
to be appropriated, for grants under subsection (a), $4,000,000 
for each of fiscal years 2019 through 2023. 
SEC. 3204. DELIVERY OF A CONTROLLED SUBSTANCE BY A PHARMACY 
TO BE ADMINISTERED BY INJECTION OR IMPLANTATION. 
(a) IN GENERAL.—The Controlled Substances Act is amended 
by inserting after section 309 (21 U.S.C. 829) the following: 
‘‘DELIVERY OF A CONTROLLED SUBSTANCE BY A PHARMACY TO AN 
ADMINISTERING PRACTITIONER 
‘‘SEC. 309A. (a) IN GENERAL.—Notwithstanding section 102(10), 
a pharmacy may deliver a controlled substance to a practitioner 
in accordance with a prescription that meets the requirements 
of this title and the regulations issued by the Attorney General
H. R. 6—53 
under this title, for the purpose of administering the controlled 
substance by the practitioner if— 
‘‘(1) the controlled substance is delivered by the pharmacy 
to the prescribing practitioner or the practitioner administering 
the controlled substance, as applicable, at the location listed 
on the practitioner’s certificate of registration issued under 
this title; 
‘‘(2) the controlled substance is to be administered for the 
purpose of maintenance or detoxification treatment under sec-
tion 303(g)(2) and— 
‘‘(A) the practitioner who issued the prescription is 
a qualifying practitioner authorized under, and acting 
within the scope of that section; and 
‘‘(B) the controlled substance is to be administered 
by injection or implantation; 
‘‘(3) the pharmacy and the practitioner are authorized to 
conduct the activities specified in this section under the law 
of the State in which such activities take place; 
‘‘(4) the prescription is not issued to supply any practitioner 
with a stock of controlled substances for the purpose of general 
dispensing to patients; 
‘‘(5) except as provided in subsection (b), the controlled 
substance is to be administered only to the patient named 
on the prescription not later than 14 days after the date of 
receipt of the controlled substance by the practitioner; and 
‘‘(6) notwithstanding any exceptions under section 307, the 
prescribing practitioner, and the practitioner administering the 
controlled substance, as applicable, maintain complete and 
accurate records of all controlled substances delivered, received, 
administered, or otherwise disposed of under this section, 
including the persons to whom controlled substances were deliv-
ered and such other information as may be required by regula-
tions of the Attorney General. 
‘‘(b) MODIFICATION OF NUMBER OF DAYS BEFORE WHICH CON-
TROLLED SUBSTANCE SHALL BE ADMINISTERED.— 
‘‘(1) INITIAL
2-YEAR
PERIOD.—During the 2-year period 
beginning on the date of enactment of this section, the Attorney 
General, in coordination with the Secretary, may reduce the 
number of days described in subsection (a)(5) if the Attorney 
General determines that such reduction will— 
‘‘(A) reduce the risk of diversion; or 
‘‘(B) protect the public health. 
‘‘(2) MODIFICATIONS AFTER SUBMISSION OF REPORT.—After 
the date on which the report described in section 3204(b) of 
the SUPPORT for Patients and Communities Act is submitted, 
the Attorney General, in coordination with the Secretary, may 
modify the number of days described in subsection (a)(5). 
‘‘(3) MINIMUM NUMBER OF DAYS.—Any modification under 
this subsection shall be for a period of not less than 7 days.’’. 
(b) STUDY AND REPORT.—Not later than 2 years after the date 
of enactment of this section, the Comptroller General of the United 
States shall conduct a study and submit to Congress a report 
on access to and potential diversion of controlled substances 
administered by injection or implantation. 
(c) TECHNICAL AND CONFORMING AMENDMENT.—The table of 
contents for the Comprehensive Drug Abuse Prevention and Control